Author

Paul Pollack 1

1 Janssen Research and Development, LLC, Spring House, United S

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet, Bruce E. Sands, William Sandborn, Peter D.R. Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, Vipin Arora, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE

Geert R. D'Haens, Stefan Schreiber, Edouard Louis, Bruce E. Sands, Elisa Gomez Valderas, Debra Miller, Noah Agada, April Naegeli, Paul Pollack, Jochen Schmitz, Janneke van der Woude, Jaroslaw Kierkuś, William Sandborn

Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Ruth Belin, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Geert R. D'Haens, Maria T. Abreu, Ruth Belin, Elisa Gomez Valderas, Debra Miller, April Naegeli, Vipin Arora, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY OF USTEKINUMAB FOR INDUCTION AND MAINTENANCE OF ENDOSCOPIC HEALING IN PATIENTS WITH CROHN?S DISEASE

Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Stephen B Hanauer, Douglas C. Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary, Brian G. Feagan, William Sandborn

EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB

William Sandborn, Bruce E. Sands, Pieter Hindryckx, Monika Fischer, Kim Isaacs, April Naegeli, Debra Miller, Elisa Gomez Valderas, Noah Agada, Paul Pollack, Geert R. D'Haens

IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Rish Pai, Gert De Hertogh, Walter Reinisch, Noam Harpaz, Brian Feagan, Noah Agada, Paul Pollack, Lai Shan Chan, Marijana Protic, Fernando Magro

Impact of Mirikizumab Treatment on Inflammatory Bowel Disease Questionnaire Scores in Patients with Moderate to Severely Active Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Edward V. Loftus, Paul Pollack, Theresa Hunter, Mingyang Shan, Deanilee Deckard, Raymond Cross, Lai Shan Chan

MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Miguel Regueiro, Mingyang Shan, Paul Pollack, Lai Shan Chan, Pieter Hindryckx, Theresa Hunter Gibble, Monika Fischer, David T. Rubin, Deanilee Deckard

Item 1 - 10 / 18
1
2